FDA Approves Nucala for Hypereosinophilic Syndrome
The FDA has approved Nucala (mepolizumab; GlaxoSmithKline) for the treatment of hypereosinophilic syndrome (HES) for 6 months or longer without another identifiable non-blood related cause of the disease in patients aged 12 years and older.